Monday April 22, 2013
Amgen, Inc., a California-based biotechnology company, has
agreed to pay the United States $24.9 million to settle allegations
that it violated the False Claims Act for marketing Aranesp to
treat anemia in nursing home residents. Aranesp may be
indicated in residents who have anemia associated with conditions
such as renal failure, dialysis or chemotherapy but not necessarily
anemia from other causes. The government alleged that Amgen
distributed materials to consultant pharmacists and nursing home
staff encouraging the use of Aranesp for patients who did not have
anemia associated with chronic renal failure.
Please see the attached release from the U. S. Department of
Justice for additional details.